Skip to main content
SpringerLink
Log in

Combined nivolumab + ipilimumab in cancer treatment: high risk of adverse events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zhao X, et al. Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis Frontiers in Oncology : 15 Jul 2022. Available from: URL: https://doi.org/10.3389/fonc.2022.877434

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Combined nivolumab + ipilimumab in cancer treatment: high risk of adverse events. Reactions Weekly 1916, 8 (2022). https://doi.org/10.1007/s40278-022-19467-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-19467-y

Search

Navigation